{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T00:59:06Z","timestamp":1794445146589,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100030970","name":"Janssen UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030970","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"DOI":"10.1186\/s12884-025-07208-9","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T08:26:11Z","timestamp":1738657571000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Patient experience and burden of haemolytic disease of the foetus and newborn: a systematic review"],"prefix":"10.1186","volume":"25","author":[{"given":"P.","family":"Maurice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"McCallion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fitzgibbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. N.","family":"Barthelmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Karmous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. J.","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. R.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Noel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andras","family":"Borsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Jouannic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"7208_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2147\/PHMT.S327032","volume":"12","author":"AK Myle","year":"2021","unstructured":"Myle AK, Al-Khattabi GH. Hemolytic disease of the Newborn: a review of current trends and prospects. Pediatr Health Med Ther. 2021;12:491\u20138.","journal-title":"Pediatr Health Med Ther"},{"issue":"1","key":"7208_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.5582\/irdr.2019.01094","volume":"9","author":"A Agrawal","year":"2020","unstructured":"Agrawal A, Hussain KS, Kumar A. Minor blood group incompatibility due to blood groups other than rh(D) leading to hemolytic disease of fetus and newborn: a need for routine antibody screening during pregnancy. Intractable Rare Dis Res. 2020;9(1):43\u20137.","journal-title":"Intractable Rare Dis Res"},{"issue":"2","key":"7208_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/vox.12265","volume":"109","author":"M de Haas","year":"2015","unstructured":"de Haas M, Thurik FF, Koelewijn JM, van der Schoot CE. Haemolytic disease of the fetus and newborn. Vox Sang. 2015;109(2):99\u2013113.","journal-title":"Vox Sang"},{"issue":"1","key":"7208_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12884-022-05329-z","volume":"23","author":"DP de Winter","year":"2023","unstructured":"de Winter DP, Kaminski A, Tjoa ML, Oepkes D. Hemolytic disease of the fetus and newborn: systematic literature review of the antenatal landscape. BMC Pregnancy Childbirth. 2023;23(1):12.","journal-title":"BMC Pregnancy Childbirth"},{"issue":"1","key":"7208_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/0973-6247.75963","volume":"5","author":"S Basu","year":"2011","unstructured":"Basu S, Kaur R, Kaur G. Hemolytic disease of the fetus and newborn: current trends and perspectives. Asian J Transfus Sci. 2011;5(1):3\u20137.","journal-title":"Asian J Transfus Sci"},{"issue":"1","key":"7208_CR6","first-page":"8","volume":"8","author":"GM Liumbruno","year":"2010","unstructured":"Liumbruno GM, D\u2019Alessandro A, Rea F, Piccinini V, Catalano L, Calizzani G, et al. The role of antenatal immunoprophylaxis in the prevention of maternal-foetal anti-rh(D) alloimmunisation. Blood Transfus. 2010;8(1):8\u201316.","journal-title":"Blood Transfus"},{"key":"7208_CR7","doi-asserted-by":"publisher","first-page":"1157004","DOI":"10.3389\/fped.2023.1157004","volume":"11","author":"W Pan","year":"2023","unstructured":"Pan W, Wu H, Chen J, Mo X, Wang H, Fang Q, et al. Fetal and neonatal outcome in severe alloimmunization managed with intrauterine transfusion: 18-year experience in a tertiary referral hospital in China. Front Pediatr. 2023;11:1157004.","journal-title":"Front Pediatr"},{"key":"7208_CR8","unstructured":"Dean L. Blood groups and red cell antigens: Bethesda (MD). National Center for Biotechnology Information (US); 2005."},{"key":"7208_CR9","unstructured":"Hall V, Avulakunta ID. Hemolytic diseases of the Newborn. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2022. StatPearls Publishing LLC.; 2022."},{"issue":"4","key":"7208_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/17474086.2017.1305265","volume":"10","author":"C Zwiers","year":"2017","unstructured":"Zwiers C, van Kamp I, Oepkes D, Lopriore E. Intrauterine transfusion and non-invasive treatment options for hemolytic disease of the fetus and newborn - review on current management and outcome. Expert Rev Hematol. 2017;10(4):337\u201344.","journal-title":"Expert Rev Hematol"},{"issue":"7","key":"7208_CR11","doi-asserted-by":"publisher","first-page":"102119","DOI":"10.1016\/j.jogoh.2021.102119","volume":"50","author":"E Maisonneuve","year":"2021","unstructured":"Maisonneuve E, Dugas A, Friszer S, Toly-Ndour C, Cariot L, Dhombres F, et al. Effect of intravenous immunoglobulins to postpone the gestational age of first intrauterine transfusion in very severe red blood cell alloimmunization: a case-control study. J Gynecol Obstet Hum Reprod. 2021;50(7):102119.","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"7208_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2147\/JBM.S204128","volume":"10","author":"F Tara","year":"2019","unstructured":"Tara F, Maleki A, Taheri N, Moein Darbari S. A case of D alloimmunization in pregnancy: successfully treated solely with therapeutic plasma exchange (TPE). J Blood Med. 2019;10:251\u20133.","journal-title":"J Blood Med"},{"issue":"7","key":"7208_CR13","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/17474086.2017.1331124","volume":"10","author":"IMC Ree","year":"2017","unstructured":"Ree IMC, Smits-Wintjens V, van der Bom JG, van Klink JMM, Oepkes D, Lopriore E. Neonatal management and outcome in alloimmune hemolytic disease. Expert Rev Hematol. 2017;10(7):607\u201316.","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"7208_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ajog.2018.06.007","volume":"219","author":"C Zwiers","year":"2018","unstructured":"Zwiers C, van der Bom JG, van Kamp IL, van Geloven N, Lopriore E, Smoleniec J, et al. Postponing early intrauterine transfusion with intravenous immunoglobulin treatment; the PETIT study on severe hemolytic disease of the fetus and newborn. Am J Obstet Gynecol. 2018;219(3):291.e1-.e9.","journal-title":"Am J Obstet Gynecol"},{"key":"7208_CR15","doi-asserted-by":"crossref","unstructured":"de Winter DP, Kaminski A, Tjoa ML, Oepkes D. Hemolytic disease of the fetus and newborn: systematic literature review of the antenatal landscape. BMC Pregnancy Childbirth. 2023;23(1) (no pagination)(12).","DOI":"10.1186\/s12884-022-05329-z"},{"issue":"1","key":"7208_CR16","first-page":"25","volume":"37","author":"A Dang","year":"2023","unstructured":"Dang A. Real-world evidence: a primer. Pharmaceut Med. 2023;37(1):25\u201336.","journal-title":"Pharmaceut Med"},{"key":"7208_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.12688\/f1000research.13585.2","volume":"7","author":"S Khosla","year":"2018","unstructured":"Khosla S, White R, Medina J, Ouwens M, Emmas C, Koder T, et al. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation? F1000Res. 2018;7:111.","journal-title":"F1000Res"},{"key":"7208_CR18","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372.","DOI":"10.1136\/bmj.n71"},{"issue":"11","key":"7208_CR19","doi-asserted-by":"publisher","first-page":"760","DOI":"10.14740\/jocmr4003","volume":"11","author":"M Al-Lawama","year":"2019","unstructured":"Al-Lawama M, Badran E, Elrimawi A, Bani Mustafa A, Alkhatib H. Intravenous immunoglobulins as Adjunct Treatment to Phototherapy in Isoimmune Hemolytic Disease of the Newborn: a retrospective case-control study. J Clin Med Res. 2019;11(11):760\u20133.","journal-title":"J Clin Med Res"},{"issue":"3","key":"7208_CR20","first-page":"455","volume":"97","author":"I Bel Hadj","year":"2019","unstructured":"Bel Hadj I, Boukhris R, Khalsi F, Namouchi M, Bougmiza I, Tinsa F, et al. ABO hemolytic disease of newborn: does newborn\u2019s blood group a risk factor. Tunisie Medicale. 2019;97(3):455\u201360.","journal-title":"Tunisie Medicale"},{"issue":"4","key":"7208_CR21","first-page":"548","volume":"11","author":"KA Birchenall","year":"2013","unstructured":"Birchenall KA, Illanes SE, Lopez F, Overton T, Liebling R, Soothill PW, et al. Neonatal outcomes of pregnancies affected by haemolytic disease of the foetus and newborn and managed with intrauterine transfusion: a service evaluation. Blood Transfus. 2013;11(4):548\u201352.","journal-title":"Blood Transfus"},{"issue":"25","key":"7208_CR22","doi-asserted-by":"publisher","first-page":"10220","DOI":"10.1080\/14767058.2022.2122041","volume":"35","author":"U Blyth","year":"2022","unstructured":"Blyth U, Larsson M, Baird A, Waring G, Athiraman N. Neonatal outcomes following intrauterine transfusion for hemolytic disease of the fetus and newborn: a twenty-year service review. J Maternal-Fetal Neonatal Med. 2022;35(25):10220\u20135.","journal-title":"J Maternal-Fetal Neonatal Med"},{"issue":"12","key":"7208_CR23","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.3109\/14767058.2012.718387","volume":"25","author":"L Corvaglia","year":"2012","unstructured":"Corvaglia L, Legnani E, Galletti S, Arcuri S, Aceti A, Faldella G. Intravenous immunoglobulin to treat neonatal alloimmune haemolytic disease. J Maternal-Fetal Neonatal Med. 2012;25(12):2782\u20135.","journal-title":"J Maternal-Fetal Neonatal Med"},{"issue":"11","key":"7208_CR24","first-page":"2","volume":"26","author":"N Fallach","year":"2023","unstructured":"Fallach N, Gazit S, Iqbal S, Chodick G, Noel W, Fitzgibbon M, et al. Utilization of Healthcare Resources and costs of hemolytic disease of Fetus and Newborn (HDFN) in Israel. Value Health. 2023;26(11):2.","journal-title":"Value Health"},{"issue":"1","key":"7208_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/trf.17176","volume":"63","author":"SJ Jansen","year":"2023","unstructured":"Jansen SJ, Ree IMC, Broer L, de Winter D, de Haas M, Bekker V, et al. Neonatal sepsis in alloimmune hemolytic disease of the fetus and newborn: a retrospective cohort study of 260 neonates. Transfusion. 2023;63(1):117\u201324.","journal-title":"Transfusion"},{"issue":"3","key":"7208_CR26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0022-3476(97)80061-3","volume":"131","author":"HM Janssens","year":"1997","unstructured":"Janssens HM, de Haan MJ, van Kamp IL, Brand R, Kanhai HH, Veen S. Outcome for children treated with fetal intravascular transfusions because of severe blood group antagonism. J Pediatr. 1997;131(3):373\u201380.","journal-title":"J Pediatr"},{"key":"7208_CR27","doi-asserted-by":"publisher","first-page":"864609","DOI":"10.3389\/fped.2022.864609","volume":"10","author":"E Okulu","year":"2022","unstructured":"Okulu E, Erdeve O, Kilic I, Olukman O, Calkavur S, Buyukkale G, et al. Intravenous immunoglobulin use in hemolytic Disease due to ABO incompatibility to Prevent Exchange Transfusion. Front Pediatr. 2022;10:864609.","journal-title":"Front Pediatr"},{"issue":"1","key":"7208_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1423-0410.2010.01307.x","volume":"99","author":"ME Rath","year":"2010","unstructured":"Rath ME, Smits-Wintjens VE, Lindenburg I, Brand A, Oepkes D, Walther FJ, et al. Top-up transfusions in neonates with rh hemolytic disease in relation to exchange transfusions. Vox Sang. 2010;99(1):65\u201370.","journal-title":"Vox Sang"},{"issue":"9","key":"7208_CR29","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/vox.13090","volume":"116","author":"IMC Ree","year":"2021","unstructured":"Ree IMC, Besuden CFJ, Wintjens VEHJ, Verweij JEJT, Oepkes D, de Haas M, et al. Exchange transfusions in severe Rh-mediated alloimmune haemolytic disease of the foetus and newborn: a 20-year overview on the incidence, associated risks and outcome. Vox Sang. 2021;116(9):990\u20137.","journal-title":"Vox Sang"},{"issue":"4","key":"7208_CR30","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/aogs.12590","volume":"94","author":"S Sainio","year":"2015","unstructured":"Sainio S, Nupponen I, Kuosmanen M, Aitokallio-Tallberg A, Ekholm E, Halmesmaki E, et al. Diagnosis and treatment of severe hemolytic disease of the fetus and newborn: a 10-year nationwide retrospective study. Acta Obstet Gynecol Scand. 2015;94(4):383\u201390.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"8","key":"7208_CR31","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/j.0001-6349.2004.00394.x","volume":"83","author":"IL van Kamp","year":"2004","unstructured":"van Kamp IL, Klumper FJ, Meerman RH, Oepkes D, Scherjon SA, Kanhai HH. Treatment of fetal anemia due to red-cell alloimmunization with intrauterine transfusions in the Netherlands, 1988\u20131999. Acta Obstet Gynecol Scand. 2004;83(8):731\u20137.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"8","key":"7208_CR32","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.4103\/njcp.njcp_1_22","volume":"25","author":"G Vardar","year":"2022","unstructured":"Vardar G, Okan MA, Karadag N, Topcuoglu S, Ozalkaya E, Karatepe HO, et al. Intravenous immunoglobulin in hemolytic disease of the newborn: a moving target in time. Niger J Clin Pract. 2022;25(8):1262\u20138.","journal-title":"Niger J Clin Pract"},{"issue":"2","key":"7208_CR33","first-page":"46","volume":"101","author":"SA Walsh","year":"2008","unstructured":"Walsh SA, Yao N, El-Khuffash A, Twomey A, Molloy EJ. Efficacy of intravenous immunoglobulin in the management of haemolytic disease of the newborn. Ir Med J. 2008;101(2):46\u20138.","journal-title":"Ir Med J"},{"issue":"2","key":"7208_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ijgo.2011.12.013","volume":"117","author":"S Altunyurt","year":"2012","unstructured":"Altunyurt S, Okyay E, Saatli B, Canbahishov T, Demir N, Ozkan H. Neonatal outcome of fetuses receiving intrauterine transfusion for severe hydrops complicated by Rhesus hemolytic disease. Int J Gynecol Obstet. 2012;117(2):153\u20136.","journal-title":"Int J Gynecol Obstet"},{"issue":"10","key":"7208_CR35","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/aogs.12477","volume":"93","author":"O Simetka","year":"2014","unstructured":"Simetka O, Petros M, Lubusky M, Liska M, Dolezalkova E, Matura D, et al. Changes in middle cerebral artery velocimetry of fetuses diagnosed postnatally with mild or moderate hemolytic disease. Acta Obstet Gynecol Scand. 2014;93(10):1059\u201364.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"2","key":"7208_CR36","doi-asserted-by":"publisher","first-page":"e1411","DOI":"10.1016\/j.ajog.2011.09.024","volume":"206","author":"IT Lindenburg","year":"2012","unstructured":"Lindenburg IT, Smits-Wintjens VE, van Klink JM, Verduin E, van Kamp IL, Walther FJ, et al. Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus\/newborn: the LOTUS study. Am J Obstet Gynecol. 2012;206(2):e1411\u20138.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"7208_CR37","doi-asserted-by":"publisher","first-page":"F52","DOI":"10.1136\/fn.70.1.F52","volume":"70","author":"G Stewart","year":"1994","unstructured":"Stewart G, Day RE, Del Priore C, Whittle MJ, Turner TL, Holland BM. Developmental outcome after intravascular intrauterine transfusion for rhesus haemolytic disease. Arch Dis Child Fetal Neonatal Ed. 1994;70(1):F52\u20133.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"5","key":"7208_CR38","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/j.1469-8749.1974.tb04178.x","volume":"16","author":"W Walker","year":"1974","unstructured":"Walker W, Ellis MI, Ellis E, Curry A, Savage RD, Sawyer R. A follow up study of survivors of Rh haemolytic disease. Dev Med Child Neurol. 1974;16(5):592\u2013611.","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"7208_CR39","first-page":"518","volume":"11","author":"F Bennardello","year":"2013","unstructured":"Bennardello F, Curciarello G. Survey on the prevention and incidence of haemolytic disease of the newborn in Italy. Blood Transfus. 2013;11(4):518\u201327.","journal-title":"Blood Transfus"},{"key":"7208_CR40","doi-asserted-by":"crossref","unstructured":"Bock JE, Winkel S. A follow-up study of infants who received intra-uterine transfusions because of severe rhesus haemolytic disease. Acta Obstet et Gynecol Scand 1976;Supplement 53:37\u201340.","DOI":"10.3109\/00016347609156443"},{"key":"7208_CR41","doi-asserted-by":"crossref","unstructured":"Ree IMC, van \u2018t Oever RM, Jansen L, Lopriore E, de Haas M, van Klink JMM. School performance and behavioral functioning in children after intrauterine transfusions for hemolytic disease of the fetus and newborn. Early Hum Dev. 2021;157 (no pagination)(105381).","DOI":"10.1016\/j.earlhumdev.2021.105381"},{"issue":"7814","key":"7208_CR42","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/S0140-6736(73)90531-X","volume":"1","author":"J Richings","year":"1973","unstructured":"Richings J. Later progress of infants who received transfusions in utero for severe rhesus haemolytic disease. Lancet. 1973;1(7814):1220\u20133.","journal-title":"Lancet"},{"issue":"1","key":"7208_CR43","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1469-8749.1970.tb01854.x","volume":"12","author":"RR Stewart","year":"1970","unstructured":"Stewart RR, Walker W, Savage RD. A developmental study of cognitive and personality characteristics associated with haemolytic disease of the newborn. Dev Med Child Neurol. 1970;12(1):16\u201326.","journal-title":"Dev Med Child Neurol"},{"issue":"5","key":"7208_CR44","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jpeds.2015.07.065","volume":"167","author":"JM van Klink","year":"2015","unstructured":"van Klink JM, Lindenburg IT, Inklaar MJ, Verduin E, Koopman HM, van Kamp IL, et al. Health-related quality of life and behavioral functioning after Intrauterine Transfusion for Alloimmune Anemia. J Pediatr. 2015;167(5):1130\u2013e52.","journal-title":"J Pediatr"},{"key":"7208_CR45","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1182\/asheducation-2015.1.146","volume":"2015","author":"M Delaney","year":"2015","unstructured":"Delaney M, Matthews DC. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. Hematol Am Soc Hematol Educ Program. 2015;2015:146\u201351.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"7208_CR46","first-page":"e33724","volume":"15","author":"IS Chaitanya Kumar","year":"2023","unstructured":"Chaitanya Kumar IS, Mani A, Sriranjitha T, Muni Srikanth I, Aswathy KV, Bhakta SK, et al. Assessment of Understandability and Actionability of YouTube Videos on hemolytic disease of the Newborn. Cureus. 2023;15(1):e33724.","journal-title":"Cureus"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-025-07208-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-025-07208-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-025-07208-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T08:26:18Z","timestamp":1738657578000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-025-07208-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7208"],"URL":"https:\/\/doi.org\/10.1186\/s12884-025-07208-9","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"22 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PM and JMJ received payment from Janssen Pharmaceuticals for other works but not for this publication. JM, AB, MF, JL, WN, WK and JN are employees of Janssen Pharmaceuticals. EJH, CRM and SAM were employees of Mtech Access whilst the project was undertaken and received payment from Janssen Pharmaceuticals to carry out this review.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}